We are live on ! Find out more
CGTX icon

Cognition Therapeutics

37 hedge funds and large institutions have $13.2M invested in Cognition Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

522% more capital inflows, than outflows

Capital inflows: $3.37M | Capital outflows: $541K

350% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 2

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

3% more funds holding

Funds holding: 36 → 37 (+1)

0.36% less ownership

Funds ownership: 23.87% → 23.52% (-0.36%)

Holders
37
Holders Change
+1
Holders Change %
+2.78%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CGTX Hedge Fund Activity: Q4 2023 in Review

37 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q4 2023, worth a combined $13.2M — up 27% from $10.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CGTX positions and 4 closed out — a net gain of 3 holders — while 9 added to existing stakes and 2 trimmed.

The largest buyer was Mercer Global Advisors, adding an estimated $152K. The largest seller was Perigon Wealth Management, exiting entirely with an estimated $322K sold.

  • 37 institutional investors held Cognition Therapeutics (CGTX) as of Q4 2023, up from 36 in Q3 2023.
  • Funds reported $13.2M of Cognition Therapeutics stock for Q4 2023, up 27% quarter-over-quarter.
  • 7 funds opened new Cognition Therapeutics positions in Q4 2023 and 4 closed out, a net change of +3 holders.
  • The largest Cognition Therapeutics buyer in Q4 2023 was Mercer Global Advisors, an estimated $152K added.
  • The largest Cognition Therapeutics seller in Q4 2023 was Perigon Wealth Management, an estimated $322K sold.

Based on aggregated 13F filings for Q4 2023.